Stockscreener 앱 받기
0.5787
3.55%
-0.0213
시간 외 거래:
.60
0.0213
+3.68%
전일 마감가:
$0.60
열려 있는:
$0.596
하루 거래량:
279.58K
Relative Volume:
0.33
시가총액:
$34.43M
수익:
$2.06M
순이익/손실:
$-19.80M
주가수익비율:
-0.8034
EPS:
-0.7203
순현금흐름:
$-20.12M
1주 성능:
+5.20%
1개월 성능:
+5.99%
6개월 성능:
+65.34%
1년 성능:
-63.14%
1일 변동 폭
$0.5636
$0.596
1주일 범위
$0.5537
$0.6299
52주 변동 폭
$0.3067
$1.7599
Femasys Inc Stock (FEMY) Company Profile
명칭
Femasys Inc
전화
770-500-3910
주소
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.5787 | 35.70M | 2.06M | -19.80M | -20.12M | -0.7203 |
|
ISRG
Intuitive Surgical Inc
|
479.93 | 169.66B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
156.53 | 44.97B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
75.01 | 36.92B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
MDLN
Medline Inc
|
43.59 | 34.30B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
227.41 | 33.20B | 5.40B | 1.49B | 1.78B | 10.12 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-20 | 개시 | Laidlaw | Buy |
Femasys Inc 주식(FEMY)의 최신 뉴스
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com India
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors - TradingView
Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria
Jeremy Alexander Sipos Net Worth (2026) - GuruFocus
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges - MSN
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN
Femasys begins enrollment in pivotal trial for FemBloc device By Investing.com - Investing.com South Africa
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment - GlobeNewswire
Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts - Defense World
Femasys (NASDAQ:FEMY) Now Covered by Analysts at Lake Street Capital - Defense World
Lake Street initiates Femasys stock coverage with buy rating By Investing.com - Investing.com Australia
Lake Street initiates Femasys stock coverage with buy rating - Investing.com
FEMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FEMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FEMY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health - TipRanks
Femasys Announces FemBloc® Permanent Birth Control Has - GlobeNewswire
Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - The Globe and Mail
Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - Bitget
Sentiment Watch: Is Femasys Inc stock undervalued right nowJuly 2025 Setups & Low Risk Investment Opportunities - baoquankhu1.vn
Femasys receives CPT code approval for infertility treatment - Investing.com India
Femasys receives CPT code approval for infertility treatment By Investing.com - Investing.com Australia
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Trend Review: Can Femasys Inc benefit from deglobalization2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
AMA procedure code supports new infertility option for over 10M US women - Stock Titan
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - Bitget
Femasys (FEMY) CEO awarded 729,000 RSUs vesting through 2027 - Stock Titan
Femasys (NASDAQ: FEMY) CFO receives 342,000 restricted stock units - Stock Titan
Femasys (FEMY) CTO reports common stock and option holdings in Form 3 - Stock Titan
How cyclical is Femasys Inc.’s revenue streamJuly 2025 News Drivers & Technical Pattern Based Buy Signals - mfd.ru
Femasys : Shareholder Update – 2025 in Review - marketscreener.com
Can Femasys Inc. sustain its profitabilityJuly 2025 Weekly Recap & Risk Managed Investment Strategies - mfd.ru
Forecast Cut: What dividend growth rate does Femasys Inc offerMarket Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Femasys stock rises on new distribution partnership in Switzerland By Investing.com - Investing.com Australia
Femasys expands European presence with Swiss distribution deal By Investing.com - Investing.com Nigeria
Femasys Inc. Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - marketscreener.com
Femasys stock rises on new distribution partnership in Switzerland - Investing.com
Femasys expands European presence with Swiss distribution deal - Investing.com
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products - The Manila Times
Femasys Inc (FEMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
0.65%
자본화:
|
볼륨(24시간):